BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3415272)

  • 1. [VAMA salvage regimen (VP-16, ARA-C, MTX and L-asparaginase) in relapsed or resistant non-Hodgkin's lymphoma].
    Nagai M; Ikeda K; Akisawa M; Shimada Y; Ohnishi H; Kamano H; Sasaki K; Taoka T; Kubota Y; Tanaka T
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2773-9. PubMed ID: 3415272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
    Yamamura R; Yamane T; Aoyama Y; Nakamae H; Hasegawa T; Ohta K; Nakao Y; Ohta T; Mugitani A; Hino M
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):373-5. PubMed ID: 15045943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
    Niitsu N; Hara A; Umeda M; Shirai T
    Rinsho Ketsueki; 1993 Jul; 34(7):829-34. PubMed ID: 7689661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
    Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
    Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas].
    Domingo Albós A; Callís M; Juliá A; Vilá J; Zuazu J; Puig J; Petit J; Fernández-Sevilla A
    Sangre (Barc); 1989 Apr; 34(2):107-11. PubMed ID: 2756450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
    Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
    Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
    Miyazaki E; Takemoto Y; Kanamaru A; Kakishita E; Nagai K; Masaoka T; Shibata H; Horiuti A; Tsubaki K; Yonezawa T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):497-503. PubMed ID: 1558399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MECHOP-BM chemotherapy in the treatment of non Hodgkin's lymphoma].
    Inoue N; Miyazaki E; Okada M; Wada H; Nishimura T; Tamura S; Fujimori Y; Okamoto T; Takemoto Y; Kosaki M
    Rinsho Ketsueki; 1994 Jun; 35(6):535-40. PubMed ID: 8078187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.